国际血栓与止血学会科学与标准化委员会关于脓毒症管理中脓毒症诱导凝血病的通讯
该通讯回顾了国际血栓与止血学会(ISTH)2001年显性弥散性血管内凝血(DIC)诊断标准及2019年脓毒症诱导凝血病(SIC)评分系统。SIC用于检测脓毒症中DIC的代偿期,报告发生率约60%,为显性DIC的两倍,死亡率≥30%,可用于抗凝治疗患者选择,但抗凝疗效尚无强证据。
要点
- SIC评分系统专为检测脓毒症中DIC代偿期设计,可进展为显性DIC。
- 脓毒症患者SIC报告发生率约60%,约为显性DIC的两倍,几乎所有显性DIC患者先前均诊断为SIC。
- SIC报告死亡率≥30%,可用于抗凝治疗患者选择;肝素、抗凝血酶、血栓调节蛋白均未证实有效,需未来试验。
核心结论
- SIC评分系统用于检测脓毒症中DIC的代偿期,报告发生率约60%,为显性DIC的两倍,死亡率≥30%,可用于抗凝治疗患者选择。
- 尽管数据有限,一些研究继续提示抗凝治疗对SIC患者可能有潜在疗效,但肝素、抗凝血酶、血栓调节蛋白均未证实有效,需未来试验。
研究设计与样本
- 国际血栓与止血学会科学与标准化委员会通讯,回顾ISTH 2001年显性DIC诊断标准及2019年SIC评分系统。
主要发现
- 脓毒症患者SIC报告发生率约60%,为显性DIC的两倍。
- 几乎所有显性DIC患者先前均诊断为SIC。
- SIC报告死亡率≥30%。
- 肝素、抗凝血酶和血栓调节蛋白是抗凝候选药物,但均未证实有效。
关键数值与推荐
- ISTH于2001年发布显性DIC诊断标准,此后作为DIC失代偿期的全球标准。
- ISTH科学标准化委员会于2019年引入SIC评分系统,专为检测脓毒症中DIC的代偿期设计。
- SIC报告发生率约60%,为显性DIC的两倍;SIC报告死亡率≥30%。
临床怎么用
- SIC评分可用于脓毒症患者中筛选抗凝治疗对象,因SIC报告死亡率≥30%。
- 尽管数据有限,一些研究继续提示抗凝治疗对SIC患者可能有潜在疗效,但肝素、抗凝血酶、血栓调节蛋白均未证实有效,需未来试验。
局限性
- 原文指出抗凝治疗数据有限(Despite the limited data)。
- 原文指出肝素、抗凝血酶和血栓调节蛋白均未证实有效(none of them have proven to be effective with robust evidence)。
- 原文指出需未来试验(future trials are warranted)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disseminated intravascular coagulation (DIC) is a life-threatening complication in sepsis and other critical conditions. The International Society on Thrombosis and Haemostasis (ISTH) released the diagnostic criteria for overt DIC in 2001. Since then, ISTH overt DIC has been used as the global standard criterion for a decompensated stage of DIC. Because detecting an earlier stage of DIC would be useful for therapeutic considerations, the scientific standardization committees of the ISTH introduced the sepsis-induced coagulopathy (SIC) scoring system in 2019. The SIC scoring system is specifically designed to detect the compensated phase of DIC in sepsis, which can lead to overt DIC with disease progression. Studies examining the performance of the SIC scoring system have reported its usefulness over the past 5 years. The reported incidence of SIC was approximately 60% in patients with sepsis, which was twice as much as that of overt DIC. Almost all patients with overt DIC were diagnosed with SIC earlier. The reported mortality of SIC was ≥30% and, thus, can be used for patient selection for anticoagulant therapy. Despite the limited data, some continue to suggest the potential efficacy of anticoagulant therapy in patients with SIC. Although heparin, antithrombin, and thrombomodulin are the candidates for anticoagulation, none of them have proven to be effective with robust evidence, and future trials are warranted.
引用
- Iba T, Levi M, Thachil J, et al. Communication from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on sepsis-induced coagulopathy in the management of sepsis. J Thromb Haemost. 2022. PMID: 36695377. doi:10.1016/j.jtha.2022.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。